This page shows the latest Storm Therapeutics news and features for those working in and with pharma, biotech and healthcare.
New head of translational oncology also hired. Storm Therapeutics, the UK-based biotech specialising in modulating RNA modifying enzymes has announced that it has raised an extra £14m ($17.8m) from ... Keith Blundy. Dr Keith Blundy, chief executive of
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
He takes up a scientific advisor role at the group. Storm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor. ... Commenting on the new appointments, Keith Blundy,
UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson. ... Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics
Professor Paul Workman joins as an independent director. Drug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board. ... UK. Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent
More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...